RORABio
Private Company
Funding information not available
Overview
RORABio is a private, preclinical biotech spin-out from Case Western Reserve and Emory University, founded in 2021 (operating under a name established in 2004). The company's core asset is the RORA-Tscm platform, a proprietary manufacturing process for a stem-like T-cell population associated with improved clinical outcomes. RORABio is pursuing two primary applications: a bispecific CAR-T for multiple myeloma and a CCR5-edited T-cell therapy for HIV immune reconstitution, with the latter supported by a Gates Foundation grant to Emory. The company is led by a team with deep experience in cell therapy and oncology.
Technology Platform
Proprietary platform for manufacturing RORA-Tscm cells, a newly discovered, long-lived, stem-like memory T-cell population. The platform enables scalable expansion and genetic engineering (e.g., CAR insertion, gene editing) to create durable cell therapies.
Opportunities
Risk Factors
Competitive Landscape
In oncology, RORABio competes against established autologous CAR-T leaders (e.g., Bristol Myers Squibb, Gilead/Kite) and a wave of next-gen technologies targeting exhaustion and solid tumors. In HIV, it competes with other gene editing (e.g., CRISPR Therapeutics) and immune reconstitution approaches. Its differentiation lies in the specific stem-like T-cell subset and proprietary expansion process.